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actual indication for protons thus heavily rests on individual 
clinical and patient dependent a priori risk factors.  
 
 
 
 
Conclusion: These results demonstrate that the potential of 
proton therapy to reduce the risk of radiation pneumonitis 
requires considerable reduction in lung dose, but translation 
into clinical significance is heavily driven by patient and 
clinical a priori risk factors. Therefore, multivariable NTCP 
models should play a major role in identifying patients 
eligible for proton therapy. 
1 Appelt, Vogelius, Farr, Khalik, Bentzen. Towards 
individualized dose constraints: adjusting the QUANTEC 
radiation pneumonitis model for clinical risk factors. Acta 
Oncologica 2014;53:605. 
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Purpose or Objective: The purpose of this study is to provide 
a dosimetric assessment for the feasibility of delivering lung 
SBRT using an integrated three-source Co60 and Magnetic 
Resonance Imaging (MRI) Guided Radiation Therapy (MR-IGRT) 
System. 
 
Material and Methods: Ten lung patients who were 
previously treated with Linac-based SBRT were included. For 
each patient, GTV, PTV, cord, lungs, heart, esophagus, and 
ribs were delineated. All Linac-based SBRT plans were 
generated using VMAT and consist of 2-10 6MV Rapid Arcs. 
Patients received prescription doses of 48 Gy/4fx to 50 
Gy/5fx. The Linac-based plans were imported into the View 
Ray MR-IGRT system for planning. Three-source Co60 plans 
were generated using step-and-shoot IMRT and utilized Monte 
Carlo dose calculation including the magnetic field correction 
of 0.35T. The PTV coverage for both Linac-based three-
source Co60 SBRT plans were such that 95% of the PTV 
received 100% the prescription dose. Finally, Linac- and three 
source Co60 – based plans were evaluated using dose-volume 
constraints for critical structures and target conformity index 
(CI), homogeneity index (HI) for the PTV. 
 
Results: The differences between PTV HI for Linac- and 
three-source Co60 -based SBRT plans were not statistically 
significant, ranging from 1.05 to 1.15. Three patients with 
the CIs >1.2 had target volumes <20cc although the location 
of the target did not have much influence on meeting the 
criteria for the target conformity. For all patients, the 
critical structure doses, such as maximum cord dose (<26 
Gy), dose to <15 cc of the heart (28Gy<15cc), and <5cc of the 
esophagus (18.8 Gy<5cc) were satisfactory with both 
techniques. For lung, although both the dose to <1500cc 
(11.6 Gy<1500cc) and <1000cc (13.6Gy<1000cc) criteria were 
met with both techniques, on average, the lung volumes 
receiving the 11.6Gy and 13.6Gy were 59.5% and 61.28% 
higher with three-source Co60 as compared the Linac-based 
SBRT plans respectively (P<0.05). As expected, low dose 
portion of the DVH for all critical structures generally 
covered much higher percentage of the critical structure 
volumes with three-source Co60 SBRT plans as compared to 
the Linac-based SBRT plans. 
 
 
Conclusion: Overall, a three-source Co60 integrated MR-IGRT 
system produced comparable dose distributions to the ones 
obtained with the Linac-based lung SBRT. Further studies are 
needed to evaluate benefits of this novel MR-IGRT system for 
lung SBRT, especially its ability to image and plan in real 
time and online adaptive treatment delivery. 
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Purpose or Objective: To experimentally validate a 4D 
Monte Carlo (MC) simulation method to calculate the dose 
